VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line | 79387

VEGFR2 / NFAT Reporter - HEK293 Recombinant Cell Line | 79387 | Gentaur US, UK & Europe Disrtribition

Category: Kinase/Kinase Receptor Tyrosine

Application: • Screen for inhibitors of VEGF/VEGFR2 signaling in a cellular context • Screen for inhibitors of kinase activity of VEGFR2 in a cellular context

Background: VEGF (Vascular Endothelial Growth Factor)/VEGFR (Vascular Endothelial Growth Factor Receptor) interaction is an important mediator of angiogenesis as well as cell survival and proliferation. VEGFR2 is a tyrosine receptor kinase that plays a major role in cellular responses driven by VEGF. Targeting the kinase activity of VEGFR2 has been an attractive tool in cancer therapy based on its anti-angiogenesis effects. In addition to the kinase inhibitors, humanized monoclonal antibodies interfering with VEGF/VEGFR2 interaction have been also developed for anti-cancer treatments.

Description: Recombinant HEK-293 cells expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human VEGFR2 (Human Vascular Endothelial Growth Factor Receptor 2; KDR, FLK1; ref seq. NM_002253.1).

Product Type: Cell Line

Shippement Condition: -80°C